|
1
|
Ni Y, Shi G, Yu Y, Hao J, Chen T and Song
H: Clinical characteristics of patients with chronic obstructive
pulmonary disease with comorbid bronchiectasis: A systemic review
and meta-analysis. Int J Chron Obstruct Pulmon Dis. 28:1465–1475.
2015. View Article : Google Scholar
|
|
2
|
Smith-Blair N: Mechanisms of diaphragm
fatigue. AACN Clin Issues. 13:307–319. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Demedts IK, Demoor T, Bracke KR, Joos GF
and Brusselle GG: Role of apoptosis in the pathogenesis of COPD and
pulmonary emphysema. Respir Res. 7:532006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kirkham PA and Barnes PJ: Oxidative stress
in COPD. Chest. 144:266–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kyroussis D, Polkey MI, Keilty SE, Mills
GH, Hamnegard CH, Moxham J and Green M: Exhaustive exercise slows
inspiratory muscle relaxation rate in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med. 153:787–793. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mador MJ, Kufel TJ, Pineda LA and Sharma
GK: Diaphragmatic fatigue and high-intensity exercise in patients
with chronic obstructive pulmonary disease. Am J Respir Crit Care
Med. 161:118–123. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reid MB: Free radicals and muscle fatigue:
Of ROS, canaries, and the IOC. Free Radic Biol Med. 44:169–179.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keatings VM, Collins PD, Scott DM and
Barnes PJ: Differences in interleukin-8 and tumor necrosis
factor-alpha in induced sputum from patients with chronic
obstructive pulmonary disease or asthma. Am J Respir Crit Care Med.
153:530–534. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bozinovski S, Vlahos R, Hansen M, Liu K
and Anderson GP: Akt in the pathogenesis of COPD. Int J Chron
Obstruct Pulmon Dis. 1:31–38. 2006.PubMed/NCBI
|
|
10
|
Cao LL, Li WZ, Si XL, Sun L and Li WP:
Protective effect and mechanism of astragaloside IV on oxidative
stress injury of mesangial cells. Zhongguo Zhong Yao Za Zhi.
38:725–730. 2013.(In Chinese). PubMed/NCBI
|
|
11
|
Ji KT, Tang JF and Chai JD: Effect of
astragaloside against the oxidative damage on endothelial cells.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 31:807–810. 2011.(In Chinese).
PubMed/NCBI
|
|
12
|
Sun L, Li W, Li W, Xiong L, Li G and Ma R:
Astragaloside IV prevents damage to human mesangial cells through
the inhibition of the NADPH oxidase/ROS/Akt/NFkappaB pathway under
high glucose conditions. Int J Mol Med. 34:167–176. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang A, Zheng Y, Que Z, Zhang L, Lin S,
Le V, Liu J and Tian J: Astragaloside IV inhibits progression of
lung cancer by mediating immune function of Tregs and CTLs by
interfering with IDO. J Cancer Res Clin Oncol. 140:1883–1890. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu YY, Zhu JX, Bian T, Gao F, Qian XF, Du
Q, Yuan MY, Sun H, Shi LZ and Yu MH: Protective effects of
astragaloside IV against ovalbumin-induced lung inflammation are
regulated/mediated by T-bet/GATA-3. Pharmacology. 94:51–59. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shang L, Qu Z, Sun L, Wang Y, Liu F, Wang
S, Gao H and Jiang F: Astragaloside IV inhibits adenovirus
replication and apoptosis in A549 cells in vitro. J Pharm
Pharmacol. 63:688–694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun J, Chen XL, Zheng JY, Zhou JW and Ma
ZL: Astragaloside IV protects new born rats from anesthesia-induced
apoptosis in the developing brain. Exp Ther Med. 12:1829–1835.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu JY, Han J, Chu ZG, Song HP, Zhang DX,
Zhang Q and Huang YS: Astragaloside IV attenuates hypoxia-induced
cardiomyocyte damage in rats by upregulating superoxide dismutase-1
levels. Clin Exp Pharmacol Physiol. 36:351–357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang ZG, Wu L, Wang JL, Yang JD, Zhang J,
Zhang J, Li LH, Xia Y, Yao LB, Qin HZ and Gao GD: Astragaloside IV
prevents MPP+-induced SH-SY5Y cell death via the
inhibition of Bax-mediated pathways and ROS production. Mol Cell
Biochem. 364:209–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Liu Q, Lu L, Zhao X, Gao X and
Wang Y: Astragaloside IV stimulates angiogenesis and increases
hypoxia-inducible factor-1α accumulation via phosphatidylinositol
3-kinase/Akt pathway. J Pharmacol Exp Ther. 338:485–491. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia Y, Zuo D, Li Z, Liu H, Dai Z, Cai J,
Pang L and Wu Y: Astragaloside IV inhibits doxorubicin-induced
cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway
via activating the PI3K/Akt pathway. Chem Pharm Bull (Tokyo).
62:45–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Demoule A, Divangahi M, Danialou G,
Gvozdic D, Larkin G, Bao W and Petrof BJ: Expression and regulation
of CC class chemokines in the dystrophic (mdx) diaphragm. Am J
Respir Cell Mol Biol. 33:178–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicologic pathology. 35:495–516. 2007.
View Article : Google Scholar : PubMed/NCBI
|
